

SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (37 CFR 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431
	APPLICANT Moore et al.		
	FILING DATE October 8, 2003	GROUP 1714	

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
UR	A.A	2 5 1 9 8 8 6	08/22/1950	Charpentier et al.			
UR	A.B	2 8 3 7 5 1 8	06/03/1958	Jacob et al.			
UR	A.C	8 5 1 9 5 1	10/19/1960	Smith Kline & French Labs.			
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

UR	A.R	Dahl et al., <u>Binding Affinity of Levomepromazine and Two of its Major Metabolites to Central Dopamine and alpha-Adrenergic Receptors in the Rat</u> , PHARMACOLOGY, Vol. 74, 1981, pp. 101-104, XP009044395					
UR	A.S	Hals et al., <u>Muscarinic Cholinergic and Histamine H1 Receptor Binding of Phenothiazine Drug Metabolites</u> , LIFE SCIENCES Vol. 43, No. 5, 1988, pp. 405-412, XP002318791					
UR	A.T	Hals et al., <u>Phenothiazine Drug Metabolites: Dopamine D2 Receptor, Alpha-1 and Alpha-2 Adrenoreceptor Binding</u> , EUROPEAN JOURNAL OF PHARMACOLOGY, Vol. 125, 1986 pp. 373-381, XP009044426					

EXAMINER 	DATE CONSIDERED 8/24/2006
---	------------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33		SERIAL NO. 10/681,431	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))				APPLICANT Keith Moore			
				FILING DATE October 8, 2003		GROUP 1714	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
UB	B.R	International Search Report for PCT/US2004/O32956, <u>mailed March 10, 2005</u>					
	B.S						
	B.T						
EXAMINER  <i>Chaitan</i>				DATE CONSIDERED  <i>9/24/2006</i>			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
XANO/33SERIAL NO.  
10/681,431INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT  
Keith MooreFILING DATE  
October 8, 2003GROUP  
1714

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
<i>cll</i>	A.L	06121698	06-05-94	Japan	C12Q	1/68	Abstract only
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)


A.R	Dahl, Svein G., <u>Pharmacokinetics of methotrimeprazine after single and multiple doses</u> , Clinical Pharmacology and Therapeutics, 1976; 19:435-442
A.S	Dahl, Svein, G., <u>Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects</u> , Therapeutic Drug Monitoring, 1982; 1:33-40
A.T	Dahl, Svein G, et al., <u>Plasma and Erythrocyte Levels of Methotrimeprazine and Two of Its Nonpolar Metabolites in Psychiatric Patients</u> , Therapeutic Drug Monitoring, 1982; 4:81-87

EXAMINER

*Chait Chahal*

DATE CONSIDERED

*8/24/2006*EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Keith Moore			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE October 8, 2003		GROUP 1714	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
UR	B.R	Gennaro, Alfonso R, Ed., <u>Chapter 45 Oral Solid Dosage Forms</u> , Remington: The Science and Practice of Pharmacy, 20th Edition, 2000, Mack Publishing Co., PA, pp.878-893					
UR	B.S	Gibson, Ed., <u>Pharmaceutical Preformulation and Formulation</u> , IHS Health Group, Englewood CO, 2001 pp. 331-354, 379-458					
UR	B.T	Hals, PA et al., <u>Metabolism of levomepromazine in man</u> , European Journal of Drug Metabolism and Pharmacokinetics, 1995; 20:61-71					
EXAMINER 				DATE CONSIDERED 8/24/2006			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33		SERIAL NO. 10/681,431	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)				APPLICANT Keith Moore			
(37 CFR 1.98(b))				FILING DATE October 8, 2003		GROUP 1714	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L						
	C.M						
	C.N						
	C.O						
	C.P						
	C.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
	C.R	Sztruhar, I et al., <u>Liquid chromatographic resolution of the enantiomers of psychotropic drug levomepromazine (methotrimeprazine) with beta-cyclodextrin-bonded chiral stationary phase</u> , Journal of Pharmaceutical & Biomedical Analyses, 1993; 3:263-266
	C.S	
	C.T	

EXAMINER 	DATE CONSIDERED 8/24/2004
--------------	------------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.